TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9711804

Group type: EXPERIMENTAL
Intervention: Intramuscular rabies vaccine (conventional regimen)
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Intradermal rabies vaccine (Thai Red Cross schedule)
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Intramuscular rabies vaccine with human or equine rabies immune globulin
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Intradermal rabies vaccine with human or equine rabies immune globulin
Number of subjects: 1198
Study: 7527131

Group type: EXPERIMENTAL
Intervention: High dose aprotinin
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Low dose aprotinin
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control
Number of subjects: 99
Study: 2646918

Group type: EXPERIMENTAL
Intervention: Screening and treatment for intestinal parasite infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (examined at six months only)
Number of subjects: 0
Study: 4916790

Group type: EXPERIMENTAL
Intervention: Prednisone (20-30 mg/24 hours, average 29 mg/24 hours for at least 6 months, with some receiving it for longer)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (no prednisone)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Prednisone (combined groups)
Number of subjects: 125
Study: 29986146

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) supplementation (420 mL, 8.4 mmol inorganic nitrate (NO3‐)·day‐1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PLA) with depleted NO3‐ (0.01 mmol NO3‐·day‐1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) supplementation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 14
Study: 28147703

Group type: EXPERIMENTAL
Intervention: Gluteal activation group (GLUTE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 24
Study: 25417708

Group type: EXPERIMENTAL
Intervention: MP‐376 (levofloxacin inhalation solution)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 23147738

Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin (with or without antimicrobial baths)
Number of subjects: 1089

Group type: EXPERIMENTAL
Intervention: Chlorhexidine body washes
Number of subjects: 1089
Study: 21967362

Group type: EXPERIMENTAL
Intervention: Intravenous levetiracetam (2500 mg) with clonazepam (1 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clonazepam (1 mg) with placebo
Number of subjects: 0
Study: 20029334

Group type: EXPERIMENTAL
Intervention: Dialysis before transplant surgery
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation
Number of subjects: 220

Group type: COMPARATOR
Intervention: Heparin anticoagulation
Number of subjects: 220
Study: 17145061

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study: 15063564

Group type: EXPERIMENTAL
Intervention: Tetravalent acellular pertussis combined vaccine (DTacP-IPV; Tetravac) as second booster
Number of subjects: 234

Group type: COMPARATOR
Intervention: Pentavalent two-component acellular pertussis combined vaccine (DTacP-IPV-Hib; Pentavac)
Number of subjects: 234
Study: 11230379

Group type: EXPERIMENTAL
Intervention: Access to educational information during computerized order entry
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard order entry on paper chart (Control)
Number of subjects: 45
Study: 9696501

Group type: EXPERIMENTAL
Intervention: Lipiodol chemoembolization plus tamoxifen (40 mg)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 73
Study: 7853154

Group type: EXPERIMENTAL
Intervention: Treadmill walking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treadmill running
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treadmill walking and running
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overground walking and running
Number of subjects: 0
Study: 2675599

Group type: EXPERIMENTAL
Intervention: Antenatal dexamethasone
Number of subjects: 147

Group type: COMPARATOR
Intervention: Calf-lung surfactant extract alone
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Calf-lung surfactant extract and dexamethasone
Number of subjects: 147

Group type: COMPARATOR
Intervention: Calf-lung surfactant extract
Number of subjects: 147
Study: 1107893

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 110
Study: 31804680

Group type: EXPERIMENTAL
Intervention: Talc Poudrage (4 g during thoracoscopy under moderate sedation)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Talc Slurry (4 g via bedside chest tube with local anesthesia)
Number of subjects: 330
Study: 29922895

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No tranexamic acid (noTXA)
Number of subjects: 180
Study: 29307999

Group type: EXPERIMENTAL
Intervention: dexlansoprazole 60 mg
Number of subjects: 175

Group type: COMPARATOR
Intervention: esomeprazole 40 mg
Number of subjects: 175

Group type: COMPARATOR
Intervention: none
Number of subjects: 175
Study: 25931290

Group type: EXPERIMENTAL
Intervention: Sensory Adapted Dental Environment (SADE)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Regular Dental Environment (RDE)
Number of subjects: 44
Study: 22954234

Group type: COMPARATOR
Intervention: Excel stents
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Dual DES
Number of subjects: 346
Study: 21310075

Group type: EXPERIMENTAL
Intervention: Open MR scanner
Number of subjects: 2000000

Group type: COMPARATOR
Intervention: Closed short-bore MR scanner with 97% noise reduction
Number of subjects: 2000000
Study: 19578654

Group type: EXPERIMENTAL
Intervention: Minimization procedure for treatment allocation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Altered arrival order of patients
Number of subjects: 0
Study: 16430775

Group type: EXPERIMENTAL
Intervention: Misola (731 +/- 7 kcal/day)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Spiruline plus traditional meals (748 +/- 6 kcal/day)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Spiruline plus Misola (767 +/- 5 kcal/day)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Traditional meals only (722 +/- 8 kcal/day)
Number of subjects: 550
Study: 14993087

Group type: EXPERIMENTAL
Intervention: Advocacy activities to counter environmental-level smoking influences
Number of subjects: 10

Group type: COMPARATOR
Intervention: Drug and alcohol abuse prevention education
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Advocacy activities
Number of subjects: 10
Study: 15229337

Group type: EXPERIMENTAL
Intervention: CYP19 11‐repeat alleles (2 alleles)
Number of subjects: 173

Group type: COMPARATOR
Intervention: CYP19 11‐repeat alleles (0 alleles)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: COMT Met/Met genotype
Number of subjects: 173

Group type: COMPARATOR
Intervention: COMT Val/Val genotype
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: COMT Val/Val genotype with at least one CYP19 11‐repeat allele
Number of subjects: 173

Group type: COMPARATOR
Intervention: Neither genotype/allele
Number of subjects: 173
Study: 10977012

Group type: EXPERIMENTAL
Intervention: L+G (insulin lispro + glyburide)
Number of subjects: 135

Group type: COMPARATOR
Intervention: NPH+G (bedtime NPH insulin + glyburide)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: All therapies
Number of subjects: 135
Study: 9384424

Group type: EXPERIMENTAL
Intervention: Injection of 40 mg methylprednisolone with 1% lidocaine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Saline solution with 1% lidocaine (control group)
Number of subjects: 58
Study: 1586601

Group type: EXPERIMENTAL
Intervention: Etretinate 25 mg orally daily for 6 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 3543432

Group type: EXPERIMENTAL
Intervention: S6472 (375 mg, 2 times daily for 7 days)
Number of subjects: 248

Group type: COMPARATOR
Intervention: CCL (250 mg, 3 times daily for 7 days)
Number of subjects: 248
Study: 3396471

Group type: EXPERIMENTAL
Intervention: Cefotaxime 2g 8‐hourly
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cefoxitin 2g 6‐hourly
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Clindamycin (900 mg 8‐hourly) and gentamicin 3 to 5 mg/kg/day in divided doses 8‐hourly
Number of subjects: 75
Study: 31804108

Group type: EXPERIMENTAL
Intervention: Capnometry-assisted antihyperventilation respiratory training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Wait list (control group)
Number of subjects: 80
Study: 31985099

Group type: EXPERIMENTAL
Intervention: Catheter ablation (ABL group)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Conventional pharmacotherapy (CNT group)
Number of subjects: 85
Study: 31668885

Group type: EXPERIMENTAL
Intervention: MFGM + LF (bovine milk fat globule membrane and lactoferrin in infant formula)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Control (cow's milk‐based infant formula)
Number of subjects: 451
Study: 28151797

Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection
Number of subjects: 775
Study: 26498227

Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23371785

Group type: EXPERIMENTAL
Intervention: Oat-treated group (beta glucan‐containing oat cereal)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Oat-treated group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 21549465

Group type: EXPERIMENTAL
Intervention: Heart failure severity classified using the IDS of the ICED scoring system
Number of subjects: 1846
Study: 19438397

Group type: EXPERIMENTAL
Intervention: Efavirenz (600 mg per day)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Nevirapine (400 mg per day)
Number of subjects: 142
Study: 17447829

Group type: EXPERIMENTAL
Intervention: Paliperidone ER 3-12 mg/day for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16398720

Group type: EXPERIMENTAL
Intervention: Stenosis group
Number of subjects: 101

Group type: COMPARATOR
Intervention: Flow group
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study: 11490241

Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 132

Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 132
Study: 9669447

Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Urapidil (30 mg)
Number of subjects: 20
Study: 8001719

Group type: EXPERIMENTAL
Intervention: Group A (volunteers for military service)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Group B (non-volunteers for military service)
Number of subjects: 145
Study: 3354367

Group type: EXPERIMENTAL
Intervention: Surgical intervention (emergency surgery)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 15
Study: 30632220

Group type: EXPERIMENTAL
Intervention: Valerian root extract (VRE) 100 mg thrice daily
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 29245275

Group type: EXPERIMENTAL
Intervention: S-1 plus radiotherapy (60-66 Gy/30 to 33 fractions)
Number of subjects: 88

Group type: COMPARATOR
Intervention: S-1 plus cisplatin plus radiotherapy (60-66 Gy/30 to 33 fractions)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: S-1 plus radiotherapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: S-1 plus cisplatin plus radiotherapy
Number of subjects: 88
Study: 25927378

Group type: EXPERIMENTAL
Intervention: PPF‐LLIN (permethrin with pyriproxyfen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: LLIN (standard permethrin-treated long-lasting insecticidal net)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPF‐LLIN
Number of subjects: 0
Study: 23659225

Group type: EXPERIMENTAL
Intervention: Testimonial messages with affective arguments
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Testimonial messages with instrumental arguments
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Rhetorical messages with affective arguments
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Rhetorical messages with instrumental arguments
Number of subjects: 81
Study: 21228822

Group type: EXPERIMENTAL
Intervention: Telemetric BP monitoring (TBPM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 19641313

Group type: EXPERIMENTAL
Intervention: Very early mobilisation (VEM), commencing <24 hours
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 71
Study: 16447240

Group type: EXPERIMENTAL
Intervention: High-dose doxycycline (100 mg twice daily) plus methotrexate (MTX)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline (20 mg twice daily) plus methotrexate (MTX)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 66
Study: 15284947

Group type: EXPERIMENTAL
Intervention: Alveofact(R) (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Survanta(R) (n = 25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both Alveofact(R) and Survanta(R)
Number of subjects: 50
Study: 11461801

Group type: EXPERIMENTAL
Intervention: High dose of investigational drug
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose of investigational drug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Investigational drug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control (e.g., carbamazepine or valproate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigational drug (high dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigational drug (low dose)
Number of subjects: 0
Study: 9490558

Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rhEPO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: oral iron therapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhEPO
Number of subjects: 0
Study: 7930915

Group type: EXPERIMENTAL
Intervention: Pilocarpine mouthwash (5 mg three times a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Artificial saliva (Saliva Orthana)
Number of subjects: 20
Study: 3555627

Group type: EXPERIMENTAL
Intervention: Methylene blue, 15 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31200814

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 628
Study: 28760787

Group type: EXPERIMENTAL
Intervention: Decision support interventions including patient decision aids for primary endocrine therapy vs surgery/antioestrogen therapy and chemotherapy vs no chemotherapy, and a clinical treatment outcomes algorithm for clinicians.
Number of subjects: 0
Study: 24038574

Group type: EXPERIMENTAL
Intervention: Structured group reading programme
Number of subjects: 41
Study: 23663881

Group type: EXPERIMENTAL
Intervention: Hepatitis B immunoglobulin (HBIG; three 200 IU intramuscular injections given at four-week intervals starting from gestation week 28)
Number of subjects: 1355

Group type: COMPARATOR
Intervention: No HBIG injection
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 1355

Group type: COMPARATOR
Intervention: Artificial formula feeding
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: HBeAg-positive mothers
Number of subjects: 1355

Group type: COMPARATOR
Intervention: HBeAg-negative mothers
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: HBV DNA-positive mothers
Number of subjects: 1355

Group type: COMPARATOR
Intervention: HBV DNA-negative mothers
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: Maternal serum HBV DNA ≥ 10⁷ copies/mL
Number of subjects: 1355

Group type: COMPARATOR
Intervention: Maternal serum HBV DNA 10³-10⁶ IU/ml
Number of subjects: 1355

Group type: COMPARATOR
Intervention: Maternal serum HBV DNA < 10³ IU/ml
Number of subjects: 1355
Study: 21205884

Group type: EXPERIMENTAL
Intervention: Motion cues for detecting inflation/deflation of rigid and flexing cylinders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computational model based on motion perspective
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asymmetric velocity profiles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Practice with motion cues
Number of subjects: 0
Study: 19701510

Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond
Number of subjects: 14

Group type: COMPARATOR
Intervention: Clearfil SE Bond
Number of subjects: 14
Study: 17374672

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3.4 +/- 1.1 mL/d)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 64
Study: 15515337

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling device at lateral force of 0.5 N
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling device at lateral force of 2.0 N
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Curets at lateral force of 0.5 N
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Curets at lateral force of 2.0 N
Number of subjects: 102

Group type: COMPARATOR
Intervention: Untreated samples (control)
Number of subjects: 102
Study: 11136912

Group type: EXPERIMENTAL
Intervention: Spermidine levels in patients with focal cerebral ischemia
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 16
Study: 9141919

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 0

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 0
Study: 8179165

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 67

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 67

Group type: COMPARATOR
Intervention: Midazolam/Fentanyl
Number of subjects: 67
Study: 2896423

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil (50 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous sufentanil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epidural morphine
Number of subjects: 0
Study: 31841875

Group type: EXPERIMENTAL
Intervention: Resilient Youth with NF (RY-NF)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Health Education for NF (HE-NF)
Number of subjects: 51
Study: 29723105

Group type: EXPERIMENTAL
Intervention: Probiotic administration for 4 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo administration for 4 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 45
Study: 26583954

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - 10 sessions
Number of subjects: 181
Study: 25520127

Group type: EXPERIMENTAL
Intervention: 7‐day standard triple therapy plus bismuth and probiotic
Number of subjects: 100

Group type: COMPARATOR
Intervention: 7‐day standard triple therapy with placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 14‐day standard triple therapy plus bismuth and probiotic
Number of subjects: 100
Study: 22906281

Group type: EXPERIMENTAL
Intervention: Ischaemic postconditioning (4 episodes of inflation and deflation of the angioplasty balloon)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no additional intervention)
Number of subjects: 62
Study: 20533525

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 128
Study: 18698245

Group type: EXPERIMENTAL
Intervention: PEG interferon alpha 2b (1.0 microg/kg per week), ribavirin (800 mg/d) plus amantadine (200 mg/d)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PEG interferon alpha 2b (1.0 microg/kg per week) plus ribavirin (800 mg/d)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall treatment (both groups)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patients who achieved SVR
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nonresponders
Number of subjects: 50
Study: 15854180

Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha-2b combined with lamivudine 100 mg/day
Number of subjects: 300

Group type: COMPARATOR
Intervention: pegylated interferon alpha-2b combined with placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha-2b
Number of subjects: 300
Study: 12440763

Group type: EXPERIMENTAL
Intervention: Monitoring with 24-hour Holter ECG on the second postoperative day-evening-night
Number of subjects: 44
Study: 10472473

Group type: EXPERIMENTAL
Intervention: Active low-power laser (50 mW, 830 nm, 10 min per session)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo low-power laser
Number of subjects: 49
Study: 8740313

Group type: EXPERIMENTAL
Intervention: rHuEPO 900 U kg‐1 week‐1 with 6 mg kg‐1 day‐1 of iron for 4 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 29
Study: 1554117

Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Morphine (5 mg)
Number of subjects: 150
Study: 3893343

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 12866

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 12866
Study: 31350701

Group type: EXPERIMENTAL
Intervention: IoCRRT
Number of subjects: 60

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IoCRRT (per-protocol analysis)
Number of subjects: 60

Group type: COMPARATOR
Intervention: SOC (per-protocol analysis)
Number of subjects: 60
Study: 29342163

Group type: EXPERIMENTAL
Intervention: Doxylamine-pyridoxine (10 mg doxylamine and 10 mg pyridoxine, taken 2-4 times per day for 14 days)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (identical tablet taken with the same instructions)
Number of subjects: 140
Study: 24222508

Group type: EXPERIMENTAL
Intervention: Four-factor version of the Partner Interaction Questionnaire (PIQ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-factor version of the Partner Interaction Questionnaire (PIQ)
Number of subjects: 0
Study: 22271159

Group type: EXPERIMENTAL
Intervention: 20 mg dapagliflozin
Number of subjects: 54

Group type: COMPARATOR
Intervention: Simvastatin (40 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Valsartan (320 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Warfarin (25 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Digoxin (0.25 mg)
Number of subjects: 54